Cleo Diagnostics

September 2023 Quarterly Activities Report

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to provide the market with an update on activities in the September 2023 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.


Highlights

  • U.S.patent granted for key novel ovarian cancer biomarker supporting CLEO's commercialisation pathway into its primary U.S. target market
  • Early progress delivered against development program with the selection of biomarkers panel for Cleo’s ovarian cancer test-kit finalised
  • Antibody development advanced increasing confidence for commercial assay development and upscaling for commercial manufacturing
  • Evaluation of four commercial antibody manufacturing partners progressed in late stage as part of a robust tender process
  • Board capacity enhanced with Chief Scientific Officer and Executive Director, Dr Andrew Stephens, expanding responsibilities to full-time
  • A$10.73M cash at bank at 30 September 2023
U.S. PATENT

The granted Patent (U.S. Patent No: US 11,725,048, "CXCL10 Binding Proteins and Compositions Thereof”) covers CLEO proprietary biomarkers and antibody formulations, which comprise the core technology of the Company’s ovarian cancer diagnostic blood test. This Patent family is directed towards C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and methods of diagnosing a condition, such as a malignancy, comprising determining a level of CXCL10 in a subject. Determination of the level of CXCL10 may also be utilised to monitor tumour burden, malignancy progression or likelihood of tumour recurrence in a subject.

The U.S. Patent expands the Company’s Intellectual Property (IP) portfolio, adding to the patent granted in Australia earlier this year (patent number 2020404453). Additional patent applications are currently pending in Europe, China, India, Japan, Korea, Israel, New Zealand and Singapore.

U.S. MARKET OPPORTUNITY

The U.S. is the largest diagnostic market in the world, and represents the Company’s primary target market for its potentially lifesaving simple diagnostic blood test. Ovarian cancer survival rates are much lower than other cancers that affect women, largely due to the fact that existing testing is insufficient to identify early stage cancers or differentiate from benign disease. Diagnosis is only made following radical surgery to remove the ovaries. The 5 year survival rate for ovarian cancer is 49%, compared to 92% for breast cancer1 where early detection screening exists.

A significant unmet clinical need exists and CLEO plans to bring to market a suite of ovarian cancer diagnostic blood tests based on the novel patented CXCL10 biomarker, which is expressed early and at high levels by ovarian cancers, but not in non-malignant disease. The tests aim to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by pathology laboratories worldwide.

The U.S. Patent complements CLEO’s regulatory approval strategy designed to access target markets and secure a path to reimbursement approvals in the future. The Company is also currently preparing for the submission of a 510(k) U.S. Food and Drug Administration (FDA) application.

CLEO is initially targeting the delivery of its blood test for the surgical triage market, however has a staged execution strategy that de-risks a pathway to all ovarian cancer diagnostic markets:

  • Surgical Triage Distinguishes benign from malignant disease to allow appropriate design of treatment before surgical intervention is considered;
  • Recurrence Identifies relapse for earlier intervention to control/manage disease progression
  • High Risk Screening Testing women with known BRCA status or extensive family history; and
  • Early Stage Screening Systematic national screening to identify early stage ovarian cancers in patients without symptoms, to allow medical intervention before cancer spreads.

Early detection is vital. When ovarian cancers are diagnosed at stage 1, patients have over a 90% 5 year survival rate. However, this rate reduces rapidly to <40% if diagnosed once the cancer has spread beyond the ovaries.

TEST-KIT BIOMARKERS PANEL FINALISED

Cleo has finalised the selection of biomarkers to be used in its ovarian cancer test-kit, along with completing the development for a prototype of the proprietary scoring algorithm. The performance metrics of the test were evaluated in a clinical study of 334 patients, the results of which are being prepared for publication in a peer-reviewed medical journal. The Company expects the publication outcome to be reported to the market by the end of CY2023. The data cannot be released prior to publication due to the nature of the peer-review process. Concurrently, Cleo is also preparing a further patent application based on the findings.


Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

COV:AU
The Conversation (0)
CLEO Further Expands Ovarian Cancer Trial with Siles Health

CLEO Further Expands Ovarian Cancer Trial with Siles Health

Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles Health

Download the PDF here.

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Download the PDF here.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×